Shanghai RAAS shareholder increases stake, triggering 1% threshold

Haiyingkang (Qingdao) Medical Technology, the controlling shareholder of Shanghai RAAS Blood Products, has increased its stake in the company, triggering a 1% equity change announcement. Between March 7, 2025, and March 12, 2025, Haiyingkang acquired 23,284,400 shares through centralized competitive bidding on the Shenzhen Stock Exchange, representing 0.35% of the company's total share capital. This increased Haiyingkang's voting rights from 27.70% to 28.05%. The share acquisition, valued at 16,034,810 RMB excluding transaction costs, is part of a larger plan announced on March 4, 2025, to increase its holdings by between 250 million and 500 million RMB. As of March 12, 2025, Haiyingkang directly holds 21.46% of Shanghai RAAS, and controls a total of 28.05% of shares through voting rights entrusted by Grifols, S.A. Haiyingkang has pledged not to reduce holdings within a statutory period.